Optimized citrullinated II-type collagen polypeptide and application thereof

Through optimized citrulline-type II collagen polypeptide, extended residence time through octadecanoic acid modification and applied in the form of a nasal drop preparation, the problem of short drug residence time and major side effects in RA treatment is solved, and effective immunity is achieved Tolerate and reduce inflammatory cytokine levels, significantly relieve RA symptoms and reduce side effects.

CN118930638AActive Publication Date: 2024-11-12PEOPLES HOSPITAL PEKING UNIV
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202411021143.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-08-22
Filing Date
2024-07-29
Publication Date
2024-11-12
Estimated Expiration
2044-07-29

AI Technical Summary

Technical Problem

The existing RA treatment drugs have great side effects, the drug residence time is short, and it cannot effectively interfere with joint damage, and traditional drugs are expensive or have the risk of opportunistic infection.

Method used

Provides an optimized citrulline-type II collagen polypeptide that extends drug residence time by octadecanoic acid modification and is used in the form of a nasal drop preparation to induce immune tolerance, reduce inflammatory cytokine levels, and increase inflammatory cells Factor level.

Benefits of technology

It extends the half-life of the drug, significantly alleviates the arthritis manifestations in RA model mice, reduces the proportion of Th1 and Th17 cells, increases the proportion of regulatory B cells, reduces the level of inflammatory cytokines, improves the therapeutic effect, reduces side effects, and improves patient acceptance .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930638A_ABST
    Figure CN118930638A_ABST
Patent Text Reader

Abstract

The invention discloses an optimized citrullinated II-type collagen polypeptide and an application of the optimized citrullinated II-type collagen polypeptide. Wherein the amino acid sequence of the polypeptide is Ste-QYMitADQAAGGLR (SEQ ID NO.1), the N end of glutamine Q in the sequence is connected with octadecanoic acid Ste, and citrulline Cit modification is carried out on the fourth site in the sequence. The citrullinated II-type collagen polypeptide disclosed by the invention is long in drug half-life period, capable of effectively treating rheumatoid arthritis and small in side effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to an optimized citrullinated type II collagen polypeptide and an application thereof. Background Art

[0002] Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease with the main clinical features of synovitis, pannus formation, autoantibody production (rheumatoid factor and anti-citrullinated protein antibodies), articular cartilage and bone destruction, which ultimately lead to joint deformity and loss of function. RA also increases the risk of other diseases, such as cardiovascular diseases such as myocardial infarction and stroke. Epidemiological studies have shown that the prevalence of RA is 0.5-1.0% worldwide. In China, the prevalence of RA is 0.28%, and the total number of patients is about 5 million. The male-to-female ratio is about 1:4, and the prevalence increases with age, especially in middle-aged and older women. The incidence of disability and functional limitation in RA patients is as high as 77.6%, and it increases with the duration of the disease, which brings a heavy burden to the patient's family and society.

[0003] RA treatment drugs include non-steroidal anti-inflammatory drugs (NSAIDs), disease modifying anti-rheumatoid drugs (DMARDs), glucocorticoids and other drugs, and patients need to take medication for life. NSAIDs can relieve pain and reduce symptoms, but cannot interfere with joint damage. Traditional DMARDs such as methotrexate can delay arthritis lesions, but they usually take effect slowly and their mechanism of action is still unclear; biological DMARDs such as TNF-α inhibitors and targeted synthetic DMARDs such as JAK inhibitors are expensive and increase the risk of opportunistic infections such as tuberculosis. Glucocorticoids can quickly improve symptoms and diseases, but long-term use can cause side effects such as osteoporosis.

[0004] In recent years, antigen-specific immunotherapy has gradually gained attention in autoimmune diseases. Unlike standard treatments that induce systemic immunosuppression, antigen-specific therapy only reprograms or deletes autoreactive T cells or B cells, inducing immune tolerance to self-antigens without compromising systemic immunity and host defense.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The purpose of the present invention is to provide a new optimized citrullinated type II collagen polypeptide for treating RA by inducing immune tolerance, in order to solve the technical problems of large side effects and short drug residence time of the existing RA treatment drugs.

[0007] The technical solution of the present invention is described in detail as follows:

[0008] In a first aspect, the present invention provides an optimized citrullinated type II collagen polypeptide, whose amino acid sequence is Ste-QYMCitADQAAGGLR (SEQ ID NO.1), wherein the N-terminus of glutamine Q in the sequence is connected to octadecanoic acid Ste, and the 4th position in the sequence is modified by citrullination Cit.

[0009] In a second aspect, the present invention provides use of the above-mentioned optimized citrullinated type II collagen polypeptide in the preparation of a drug for treating rheumatoid arthritis.

[0010] Optionally or preferably, the drug is a nasal drop preparation.

[0011] In a third aspect, the present invention provides a drug for treating rheumatoid arthritis, which contains the above-mentioned optimized citrullinated type II collagen polypeptide.

[0012] Optionally or preferably, the drug is a nasal drop preparation.

[0013] Optionally or preferably, the ingredients of the nasal drop preparation are: optimized citrullinated type II collagen polypeptide, dimethyl sulfoxide (DMSO) and water.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] 1. Long half-life. The optimized citrullinated type II collagen polypeptide provided by the present invention, after being modified with octadecanoic acid, greatly prolongs the drug residence time, with a half-life of more than 80 hours.

[0016] 2. Good immunogenicity. The optimized citrullinated type II collagen polypeptide provided by the present invention can activate peripheral blood mononuclear cells (PBMCs) of rheumatoid arthritis patients or healthy people carrying the rheumatoid arthritis risk gene HLA-DRB1 in vitro, promote the secretion of proinflammatory cytokine IL-6, and has strong antigenicity.

[0017] 3. Low irritation. The present invention uses optimized citrullinated type II collagen polypeptide to prepare a nasal drop preparation, which is less irritating to patients than injection preparations and has higher patient acceptance.

[0018] 4. Good therapeutic effect. The optimized citrullinated type II collagen polypeptide provided by the present invention can effectively treat RA. Animal experiments show that the optimized citrullinated type II collagen polypeptide of the present invention can significantly alleviate the arthritis symptoms of RA model mice and reduce the histopathological scores by nasal drops. The results of flow cytometry test showed that nasal drops of the optimized citrullinated type II collagen polypeptide of the present invention can reduce the proportion of Th1 and Th17 cells, increase the proportion of regulatory B cells (Breg); reduce the levels of inflammatory cytokines IL-6 and TNF-α, and increase the level of anti-inflammatory cytokine IL-10. BCR sequencing shows that the polypeptide can correct abnormal and unbalanced VJ, VJD combinations and CDR3.

[0019] 5. Small side effects. Histopathology shows that the optimized citrullinated type II collagen polypeptide provided by the present invention has no obvious side effects in the treatment of RA.

[0020] In summary, the present invention provides an effective new strategy for the treatment of RA, which can induce antigen-specific immune tolerance without causing obvious side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 This is a diagram showing the HPLC purification results of the optimized citrullinated type II collagen peptide Ste-citAg.

[0022] Figure 2 This is the mass spectrometry identification diagram of the optimized citrullinated type II collagen peptide Ste-citAg.

[0023] Figure 3 The degradation of non-Ste-modified citrullinated type II collagen peptide and Ste-modified optimized citrullinated type II collagen peptide in the plasma of RA patients.

[0024] Figure 4 This figure shows the effect of the optimized citrullinated type II collagen peptide Ste-citAg on the level of cytokine secretion by PBMCs in RA patients.

[0025] Figure 5 The results of the therapeutic effect of the optimized citrullinated type II collagen peptide Ste-citAg in the RA animal model, where (a) is the arthritis score of the different groups after administration, (b) is the histopathological score of the different groups after 28 days of administration, the circles in the two figures represent the Ste-IP control peptide administration group, and the squares represent the Ste-citAg administration group; (c) is the joint tissue staining results and bone tissue scan photos of the different groups after 28 days of administration.

[0026] Figure 6Figure 2 shows the results of lymphocyte subset analysis in arthritic mice after treatment with the optimized citrullinated type II collagen peptide Ste-citAg.

[0027] Figure 7 This is a graph showing changes in the B cell receptor repertoire of arthritic mice after treatment with the optimized citrullinated type II collagen peptide Ste-citAg.

[0028] Figure 8 This is a diagram showing the experimental results of tissue damage and side effects in arthritic mice after treatment with the optimized citrullinated type II collagen peptide Ste-citAg. DETAILED DESCRIPTION

[0029] In order to make the technical personnel in this field better understand the present application scheme, the present application will be clearly and completely described below in conjunction with the embodiments and drawings. Obviously, the described embodiments are only embodiments of a part of the present application, rather than all embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without making creative work should belong to the scope of protection of this application. The instruments and reagents used in the embodiments are all derived from commercial channels unless otherwise specified.

[0030] Example 1 Preparation and half-life of optimized citrullinated type II collagen polypeptide Ste-citAg

[0031] The amino acid sequence of the optimized citrullinated type II collagen polypeptide is shown in SEQ ID NO.1: Ste-QYMCitADQAAGGLR (abbreviated as Ste-citAg), in which the N-terminus of glutamine Q in the sequence is connected to octadecanoic acid Ste, and the 4th position in the sequence is modified by citrullination Cit.

[0032] The above sequence was synthesized by Shanghai Nuoyou Biotechnology Co., Ltd. using Fmoc solid phase synthesis, purified by HPLC, identified by mass spectrometry, and endotoxin was removed. The results of HPLC purification and mass spectrometry identification are as follows Figure 1 and Figure 2 shown.

[0033] The peptides without octadecanoic acid modification (citAg) and the peptides modified with octadecanoic acid (Ste-citAg) were dissolved in PBS at a concentration of 200 μM. Subsequently, the peptides were mixed with human serum (from Peking University People's Hospital) at a ratio of 50% (v / v), with a total volume of 300 μL and placed in a 1.5 ml EP tube. The reaction tubes were then placed in a shaker and incubated at 37°C with continuous shaking at 200 rpm. At each designated time point, 30 μL of the reaction mixture was taken from each replicate experiment and diluted with twice the volume of cold acetone. After a 15-minute precipitation step at -20°C, serum proteins were removed by centrifugation at 14,000g for 10 minutes (4°C). The resulting supernatant was transferred to a new tube and washed with an equal volume of ACN / H 2 O 50% (v / v) dilution. Subsequently, the solution was filtered through a 0.2 μm filter membrane and then analyzed by HPLC. The experiment was repeated 3 times in parallel.

[0034] The results showed that the peptides without octadecanoic acid Ste modification ( Figure 3 The half-life of citAg in RA patients' plasma is only 30 minutes; while the peptide modified with octadecanoic acid Ste ( Figure 3 The half-life of Ste-citAg in the plasma of RA patients is more than 80 hours.

[0035] Experiments show that when the N-terminus of glutamine Q in the above polypeptide sequence is connected to octadecanoic acid Ste, the destructive effect of proteolytic enzymes on the polypeptide is greatly reduced, the degradation rate of the polypeptide is effectively delayed, and the polypeptide is transported into the cell in a favorable manner.

[0036] Example 2 Immunogenicity of Optimized Citrullinated Type II Collagen Peptides

[0037] Experimental Materials:

[0038] Ste-citAg sequence: Ste-QYMCitADQAAGGLR (citrullinated at position 4);

[0039] Ste-Ag sequence: Ste-QYMRADQAAGGLR (not citrullinated);

[0040] Ste-IP sequence: Ste-RLGGAAQDARMYQ (irrelevant peptide, used as control peptide);

[0041] PHA: Phytohemagglutinin (positive control).

[0042] Experimental methods:

[0043] We randomly recruited 12 RA patients and performed HLA-DRB1 genotyping on them. We recruited a total of 5 RA patients with rheumatoid susceptibility genes, who carried HLA-DRB1*01:01 (2 cases) and 04:05 genes (3 cases).

[0044] 4 mL of EDTA anticoagulated blood from RA patients was obtained and PBMCs (peripheral blood mononuclear cells) were isolated by density gradient centrifugation and inoculated into 96-well plates (2*10 5 Cells / well) were added with Ste-citAg, Ste-Ag and Ste-IP (10 μg / mL) respectively, and 5 μg / mL of phytohemagglutinin (PHA) was added as a positive control. The cells were incubated at 37°C and 5% CO 2 After culturing for 5 days under the same conditions, the cell culture supernatant was obtained and the levels of IL-6, IFN-γ and IL-17A were detected by enzyme linked immunosorbent assay (ELISA).

[0045] Whole blood was collected and the HLA-DRB1 genotype was identified by Beijing Jingzhun Biotechnology Co., Ltd. to determine the SE epitope status.

[0046] Experimental results:

[0047] We co-cultured the above-mentioned different peptides with PBMCs separately and detected the levels of cytokines in the cell culture supernatant by Elisa. Figure 4 Compared with the Ste-IP control group, Ste-citAg can stimulate human peripheral blood mononuclear cells to secrete IL-6, IFN-γ and IL-17A, and is stronger than Ste-Ag, proving that Ste-citAg has good immunogenicity.

[0048] Example 3 Therapeutic effect of optimized citrullinated type II collagen polypeptide in RA animal model

[0049] The internationally recognized collagen-induced arthritis (CIA) animal model was used, and the experimental animals used were inbred DBA / 1 mice.

[0050] Bovine collagen type II (bCII) and Complete Freund's Adjuvant (CFA) / Incomplete Freund's Adjuvant (IFA) were co-emulsified and injected intradermally into mice on days 0 and 21 to induce arthritis. The mice were randomly divided into groups according to the scores on day 7 after the onset of the disease and given 10 μL Ste-citAg or Ste-IP control peptide (concentration of 2.5 mg / mL) by intranasal drops once a day for 3 weeks. The disease condition and joint phenotype scores of the mice were observed and recorded: no joint redness and swelling was scored as 0 points; 1-2 swelling of toe joints was scored as 1 point, and more than 2 points were scored as 2 points; swelling of the soles of the feet was scored as 1 point; swelling of the wrist joints was scored as 1 point; each paw could be scored up to 4 points, and each mouse could be scored up to 16 points.

[0051] After treatment, the mice were killed, and the hind paws were collected and immersed in a tissue fixative containing 4% paraformaldehyde, and then decalcified with EDTA to prepare paraffin sections, and finally HE staining was performed to evaluate the presence of synovial hyperplasia, inflammatory cell infiltration, bone destruction and their severity in the joints. Among them, normal was scored as 0 points; synovial hyperplasia and inflammatory cell infiltration were scored as 1 point; pannus formation and articular cartilage destruction were scored as 2 points; most articular cartilage destruction and subchondral bone erosion were scored as 3 points; loss of joint integrity and joint ankylosis were scored as 4 points.

[0052] The affected joints of mice were imaged using a small animal CT (Computer tomography) system to observe bone erosion.

[0053] The experimental results are as follows Figure 5 As shown in the figure, from the third day of treatment, the arthritis score of mice in the Ste-citAg group began to decrease significantly compared with the Ste-IP control peptide treatment group; at the end of treatment (day 28), the arthritis score of mice in the Ste-citAg group was significantly lower than that of mice in the control group (6.80±1.19 vs. 10.80±1.04; P<0.05). The pathological results of the toe and ankle joints showed that most of the mice in the Ste-IP group had pannus formation, articular cartilage destruction, partial loss of joint integrity, and ankylosis; only synovial hyperplasia and inflammatory cell infiltration were observed in the Ste-citAg treatment group, and articular cartilage destruction was not obvious. Its pathological score (1.15±0.35) was significantly lower than that in the Ste-IP treatment group (2.35±0.24, P=0.0178). Micro CT scanning found that the Ste-IP treatment group had very severe bone erosion, while the Ste-citAg treatment group had significantly reduced bone erosion.

[0054] Example 4 Optimized citrullinated type II collagen polypeptide regulates immune cell subset ratios and cytokine levels in CIA mice

[0055] Implementation method:

[0056] After the treatment, the mice were killed, and the spleen, draining lymph nodes, and mesenteric lymph nodes were removed and ground with a filter to obtain a single cell suspension. The changes in T and B cell subsets such as Th1, Th2, Th17, Treg, Tfh, and Breg were detected by flow cytometry.

[0057] After the treatment, the mice were anesthetized and blood was collected from their eyes. After 2 hours, the blood was centrifuged at 3500 rpm / 10 min to collect serum. The levels of IL-6, TNF-α, IL-17A, IFN-γ and other cytokines were detected by ELISA.

[0058] The experimental results are as follows Figure 6 As shown, lymphocyte subset analysis found that compared with the Ste-IP treatment group (i.e., control group), the Th1 (control group: 1.58±0.15%, Ste-citAg group: 1.25±0.16%) and Th17 (control group: 1.35±0.12%, Ste-citAg group: 1.12±0.06%) in the Ste-citAg group mice were decreased; Th2 (control group: 0.33±0.03%, Ste-citAg group: 0.55±0.10%; P=0.05) and B10 (control group: 10.60±0.58%, Ste-citAg group: 12.73±0.55%; P=0.02) were increased.

[0059] The results of cytokine detection are shown in Table 1. Compared with the control peptide Ste-IP, Ste-citAg can significantly reduce the level of proinflammatory cytokine TNF-α (Ste-IP group: 129.2±33.45pg / mL, Ste-citAg group: 45.12±26.56pg / mL); proinflammatory cytokines IL-6 and IL-17A are also reduced. The level of IL-4 is significantly increased (Ste-IP group: 1.44±0.26pg / mL, Ste-citAg: 4.26±1.25pg / mL), and the anti-inflammatory cytokine IL-10 is also increased to a certain extent.

[0060] Table 1 Cytokine detection results

[0061]

[0062]

[0063] Example 5 Optimized citrullinated type II collagen polypeptide restores B cell receptor repertoire balance

[0064] Implementation method:

[0065] After the treatment, the mice were killed, the spleen was taken to separate lymphocytes, total RNA was extracted and endogenous DNA was removed using DNase, and the first-strand cDNA was synthesized using six-base random primers, and then the second-strand synthesis reaction system was prepared to synthesize the second-strand cDNA; BCR heavy chain primers were used for multiple PCR amplification, and the PCR products were purified, end-repaired, A-tailed, and connected to sequencing adapters for PCR amplification; the constructed library was quality inspected by Agilent2100Bioanalyzer and then sequenced using Illumina HiSeq XTMTen.

[0066] The sequenced data were compared with the sequences of the V, J, and D regions of the species in the IMGT (http: / / www.imgt.org / ) database, and the expression of the V, J, and D regions, as well as the VJ and VDJ combinations in each sample were comprehensively examined; the diversity of the CDR3 amino acid clonotypes of each sample and the similarity between samples were evaluated; and the V genes, J genes, VJ combinations, VDJ combinations, and CDR3 amino acid clonotypes with significant differences between groups were analyzed. The sequencing and analysis were commissioned to Qingdao Ouyi Biomedical Technology Co., Ltd.

[0067] The experimental results are as follows Figure 6 The results showed that compared with the non-modeling group, 6 VJ combinations in the Ste-IP control group were significantly increased, and 7 VJ combinations were significantly decreased. Compared with the Ste-IP control group, after Ste-citAg treatment, 6 VJ combinations were significantly increased, and 5 VJ combinations were significantly decreased. Among them, IGHV1S21_IGHJ2, IGHV6-5_IGHJ2, and IGHV9-2-1_IGHJ2 combinations increased after modeling and decreased after treatment, which may be involved in the process of Ste-citAg treatment of CIA.

[0068] Compared with the non-modeling group, 34 VDJ combinations in the Ste-IP control group were significantly increased, and 146 VDJ combinations were significantly decreased; compared with the Ste-IP control group, after Ste-citAg treatment, 71 VDJ combinations were significantly increased, and 39 VDJ combinations were significantly decreased. Among them, the combination of IGHV1S17_IGHJ4_IGHD3-1, IGHV1-75_IGHJ1_IGHD1-1, IGHV1-19_IGHJ3_IGHD2-12, IGHV5-9_IGHJ4_IGHD5-4, IGHV2-9-2_IGHJ2_IGHD2-9, IGHV1S35_IGHJ1_IGHD3-3, IGHV1S134_IGHJ4_IGHD3-2, IGHV1S47_IGHJ4_IGHD3-2, IGHV9-3-1_IGHJ4_IGHD2-9, and IGHV9-3_IGHJ4_IGHD2-9 increased after CIA modeling and decreased after treatment, which may be involved in the process of Ste-citAg treatment of CIA.

[0069] In addition, we also compared the changes in CDR3. The results showed that the fragments of CARDNWGFAYW, CARAGTGYAMDYW, CARDAGGSYAMDYW, CAGDNWDW, and CAREDFDYW increased after modeling and decreased after treatment, which may be involved in the process of Ste-citAg treatment of CIA.

[0070] Example 6 Optimized citrullinated type II collagen polypeptide treatment does not cause significant tissue damage and side effects

[0071] Experimental methods:

[0072] After the treatment, the body weight and heart weight of the mice were measured, and the heart, liver, spleen, lung, kidney, stomach, small intestine, pancreas, and brain of the mice were taken for routine pathological analysis.

[0073] The experimental results are as follows Figure 7 The results showed that compared with the Ste-IP control group, there was no significant difference in body weight and heart weight of CIA mice after Ste-citAg treatment, and there was no obvious lesions or damage in various organs, and there was no significant difference between the groups.

[0074] These results indicate that Ste-citAg can induce antigen-specific immune tolerance, induce regulatory B cells, reduce effector T cells, and restore the balance of the immune repertoire without obvious side effects, providing a new strategy for the treatment of rheumatoid arthritis.

[0075] The invention concept is described in detail using specific examples herein, and the description of the above embodiments is only used to help understand the core idea of ​​the invention. It should be pointed out that any obvious modification, equivalent substitution or other improvement made by a person of ordinary skill in the art without departing from the invention concept should be included in the protection scope of the present invention.

Claims

1. An optimized citrullinated type II collagen polypeptide, characterized in that: The amino acid sequence is Ste-QYMCitADQAAGGLR (SEQ ID NO. 1), wherein the N-terminus of glutamine Q in the sequence is connected to octadecanoic acid Ste, and the 4th position in the sequence is modified by citrulline Cit.

2. Use of the optimized citrullinated type II collagen polypeptide according to claim 1 in the preparation of a drug for treating rheumatoid arthritis.

3. The use according to claim 2, characterized in that: The medicine is a nasal drop preparation.

4. A drug for treating rheumatoid arthritis, characterized in that: Contains the optimized citrullinated type II collagen polypeptide according to claim 1.

5. The drug according to claim 4, characterized in that The medicine is a nasal drop preparation.

6. The drug according to claim 5, characterized in that The ingredients of the nasal drop preparation are: optimized citrullinated type II collagen polypeptide, dimethyl sulfoxide (DMSO) and water.

Citation Information

Patent Citations

  • Immunomodulatory agent and uses therefor

    CA2868123A1

  • Application of polypeptides in preparation of medicament for treating or preventing rheumatoid arthritis

    CN104127859A

  • Nano micelle and application thereof

    CN108371653A

  • Citrullinated antigen-modified peptide and application thereof

    CN110041404A

  • Fatty acid modified neuropeptide S analogue, and synthesis and application thereof

    CN110437310A